• Proteoform-Specific Drug Interactions in Native Membranes

  2026-05-20

  This study introduces a native top-down mass spectrometry approach to directly characterize proteoform-specific interactions of membrane proteins, such as rhodopsin, in their native lipid environment. The findings illuminate how post-translational modifications and alternative splicing affect drug binding, with important implications for the selectivity and safety of cGMP-specific phosphodiesterase type 5 inhibitors like Sildenafil Citrate.

• (-)-JQ1: Gold-Standard Inactive Control for BET Bromodomain

  2026-05-20

  (-)-JQ1, a stereoisomer of JQ1, is the definitive inactive control for BET bromodomain inhibition. Unlike (+)-JQ1, (-)-JQ1 shows no significant BRD4 binding or functional inhibition, enabling rigorous distinction of on-target effects in epigenetics and cancer biology research.

• mRNA-LNP Induced Pyroptosis Primes Cold Tumors for Immunothe

  2026-05-19

  The study introduces a single-agent mRNA lipid nanoparticle (LNP) approach to induce pyroptosis in immunologically cold tumors, thereby enhancing their responsiveness to immune checkpoint blockade therapies. This strategy offers a promising route to activate robust antitumor immunity where conventional treatments often fail.

• Sisomicin, Netilmicin, and Dibekacin: Comparative Antibacter

  2026-05-19

  This review article critically examines the antibacterial profiles and clinical applications of sisomicin, netilmicin, and dibekacin, three systemically administered aminoglycoside antibiotics. The study highlights sisomicin’s superior activity against select Gram-negative pathogens and its pharmacological similarities to gentamicin, offering practical insights for infection research and therapeutic strategies.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-05-18

  Oliveira et al. (2025) reveal that specific angiotensin peptides, but not Angiotensin I, enhance binding of the SARS-CoV-2 spike protein to alternative host cell receptors, particularly AXL. This finding bridges renin-angiotensin system research with viral pathogenesis and highlights new mechanistic intersections relevant to cardiovascular and infectious disease research.

• Cyclophosphamide in Translational Oncology: Mechanistic Insi

  2026-05-18

  Explore Cyclophosphamide as a leading alkylating chemotherapeutic agent, with an advanced focus on its DNA cross-linking mechanism, optimized protocols, and unique applications in translational cancer research. This article delivers a deeper mechanistic and assay-centric perspective distinct from standard workflow guides.

• Genomic Instability Drives Therapeutic Heterogeneity in CRC

  2026-05-17

  This study by Cho et al. utilizes patient-derived xenograft (PDX) models to demonstrate that metastatic evolution in colorectal cancer (CRC) is accompanied by dynamic genomic and transcriptomic alterations. These changes underlie significant therapeutic heterogeneity and resistance, highlighting the need for precision approaches in colon cancer research.

• Light-Inducible RNA-Releasing Proteins for Regulated Gene Th

  2026-05-16

  The reference study presents a rationally engineered light-inducible RNA-releasing protein (LIRP) that enables precise translational control of gene therapies in vivo. By integrating optogenetic regulation at the mRNA translation level, this compact system offers new avenues for reversible, tissue-specific treatment of chronic metabolic and retinal diseases.

• Dihydroartemisinin (SKU N1713): Reliable Workflows for Cell

  2026-05-15

  This article provides scenario-driven guidance for leveraging Dihydroartemisinin (SKU N1713) in cell viability, proliferation, and cytotoxicity assays. It addresses practical laboratory challenges—such as compound solubility, mTOR signaling pathway analysis, and product reliability—while synthesizing evidence-backed recommendations for biomedical researchers. The discussion highlights APExBIO’s Dihydroartemisinin as a reproducible, high-purity solution for advanced research workflows.

• Advancing Bioaerosol Detection: Removing Pollen Spectral Int

  2026-05-15

  This study introduces a robust spectral data transformation and machine learning workflow to accurately distinguish hazardous bioaerosols from pollen using excitation–emission matrix (EEM) fluorescence spectroscopy. By eliminating pollen spectral interference, the approach enhances rapid detection of pathogens and toxins, supporting public health monitoring.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-05-14

  This study introduces a patient-specific gastric cancer assembloid that integrates tumor organoids with matched stromal cell subpopulations, providing a more physiologically relevant model of tumor heterogeneity and drug response. The platform allows for improved investigation of tumor–stroma interactions and supports personalized drug screening strategies.

• Atrial Natriuretic Peptide: Applied Workflows for Cardiovasc

  2026-05-14

  Discover how Atrial Natriuretic Peptide (ANP) elevates cardiovascular research with robust, reproducible protocols and advanced troubleshooting. This guide translates recent mechanistic insights and peer-reviewed workflows into actionable steps for maximizing assay integrity and data quality with APExBIO’s high-purity ANP peptide hormone.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP) for Advanced mRNA Delivery

  2026-05-13

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) streamlines dual-fluorescence mRNA delivery assays, letting researchers quantify uptake and translation efficiency in real time. Its immune-evasive chemistry and robust Cap 1 structure provide a decisive edge for nanoparticle validation, gene regulation studies, and troubleshooting transfection protocols.

• Fluorouracil in Advanced Colon Cancer Research: Molecular In

  2026-05-13

  Explore the molecular mechanisms and assay optimization of Fluorouracil (5-Fluorouracil) in colon cancer research. Discover how genomic heterogeneity impacts drug response, with practical guidance for experimental design and interpretation.

• HR Pathway Profiling Predicts Olaparib Sensitivity in Mesoth

  2026-05-12

  Borchert et al. (2019) identified that gene expression profiles reflecting homologous recombination repair (HRR) deficiencies—'BRCAness'—are present in a subset of malignant pleural mesothelioma (MPM) cases, correlating with enhanced sensitivity to PARP inhibition by olaparib. Their findings point to novel stratification strategies and combinatorial chemotherapy approaches in MPM, potentially improving outcomes through precision targeting of DNA repair vulnerabilities.

15079 records 1/1006 page Next 12345 下5页 Last page